NDAORALTABLET
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
7/8 — Comprehensive
GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) by Gilead Sciences is cytochrome p450 3a inhibitors [moa]. Approved for cytochrome p450 3a inhibitor [epc]. First approved in 2015.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GENVOYA is a fixed-dose combination tablet containing elvitegravir (integrase inhibitor), cobicistat (CYP3A inhibitor), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor). It is indicated for the treatment of HIV-1 infection in adults and pediatric patients. The product works through multiple mechanisms of action targeting different stages of viral replication, with cobicistat enhancing the bioavailability of elvitegravir. GENVOYA represents a modernized formulation of Gilead's earlier STRIBILD, utilizing tenofovir alafenamide instead of tenofovir disoproxil fumarate for improved renal and bone safety.
$0.6BPart D
6.9 years to LOEMechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Analysis of Crushed and Whole Tablet Genvoya
Started Apr 2019
12 enrolled
Healthy Volunteers
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
Started May 2018
0HIV/AIDS
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Started Feb 2018
25 enrolled
HIV-1-infectionHepatitis C, ChronicMethadone Dependence+6 more
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis
Started Mar 2017
101 enrolled
HIV Risk
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
Started Feb 2014
79 enrolled
HIVHBV
Worked on GENVOYA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.